Targeted Therapies
The NEW Targeted Therapies pipeline explores the frontiers of targeted therapies and drug delivery systems, offering an integrated approach to advancing these transformative technologies. Discussions will delve into the engineering of safe and effective vectors to optimize delivery of therapeutic payloads such as mRNA, cell therapies, and gene therapies; insights into the promising realm of targeted radioligand therapies, which leverage the specificity of targeted molecules combined with the potency of radioisotopes for precise cancer cell elimination, as well as next-generation protein degradation approaches, which hold the potential to combat previously "undruggable" targets. Attendees will explore fundamental principles, optimization strategies, innovative targeting mechanisms, computational approaches, and clinical translation strategies, encouraging them to push the boundaries of biomedical research and clinical applications.
January 13
January 14-15
January 15-16
KEYNOTE PRESENTATIONS:
Novel Drug Router Constructs for Large-Molecule Delivery
Jay Sarkar, PhD, Visiting Scholar, Stanford University
Advancing Radiopharmaceuticals: Clinical Trials and Infrastructure for Therapeutic Success
Mary Jessel, PhD, Senior Vice President, Global Medical Affairs, Telix Pharmaceuticals
Optimizing Payloads for Efficient Delivery of Degrader Antibody Conjugates (DACs)
Jin Wang, PhD, Director, Biochemistry and Molecular Pharmacology, Baylor College of Medicine
If you’re working in the following areas, join the Peptalk community:
- Oncology
- Radiology
- Molecular Biology
- Chemistry
- Clinical Research
- Clinical Trial Design and Management
- Radio imaging
- Companion Diagnostics and Biomarker Research
- Pharmacology
- Toxicology
- Drug Discovery and Development
- Regulatory Affairs and Compliance
- Medical Affairs
- Research & Development
- Radiopharmaceutical Production
- Supply Chain Management
- Computational Biology and Bioinformatics
- Venture Capitalists and Investments